



Sep 14, 2016

Otsuka Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.

Announcement of Co-promotion of New Glaucoma Treatment

Otsuka Pharmaceutical Co., Ltd. and Senju Pharmaceutical Co., Ltd. announce the signing of a new agreement to co-promote in Japan an additional new treatment for glaucoma and ocular hypertension.

The two companies have an existing agreement to market Mikelan ophthalmic solution and Mikelan Long-Acting ophthalmic solution, treatments developed by Otsuka for glaucoma and ocular hypertension. The new contract reflects the decision to co-promote in Japan the combined ophthalmic solution carteolol hydrochloride/latanoprost (OPC-1085EL), which has been submitted for new drug approval in Japan.

In addition, the new contract includes provisions to co-promote another future ophthalmic preparation that Senju Pharmaceutical has scheduled to enter clinical development.

Furthermore, at the signing of the contract no additional milestone or lump sum payments were made.